Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 120.81
TARO's Cash to Debt is ranked higher than
85% of the 1152 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. TARO: 120.81 )
TARO' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 120.81

Equity to Asset 0.82
TARO's Equity to Asset is ranked higher than
90% of the 1034 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. TARO: 0.82 )
TARO' s 10-Year Equity to Asset Range
Min: 0.23   Max: 0.83
Current: 0.82

0.23
0.83
Interest Coverage 283.81
TARO's Interest Coverage is ranked higher than
68% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. TARO: 283.81 )
TARO' s 10-Year Interest Coverage Range
Min: 1.47   Max: 508.04
Current: 283.81

1.47
508.04
F-Score: 7
Z-Score: 15.45
M-Score: -1.46
WACC vs ROIC
8.71%
85.78%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 59.02
TARO's Operating margin (%) is ranked higher than
99% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. TARO: 59.02 )
TARO' s 10-Year Operating margin (%) Range
Min: -27.89   Max: 56.67
Current: 59.02

-27.89
56.67
Net-margin (%) 52.31
TARO's Net-margin (%) is ranked higher than
98% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.10 vs. TARO: 52.31 )
TARO' s 10-Year Net-margin (%) Range
Min: -32.77   Max: 47.46
Current: 52.31

-32.77
47.46
ROE (%) 37.95
TARO's ROE (%) is ranked higher than
97% of the 1129 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.93 vs. TARO: 37.95 )
TARO' s 10-Year ROE (%) Range
Min: -92.98   Max: 49.88
Current: 37.95

-92.98
49.88
ROA (%) 30.63
TARO's ROA (%) is ranked higher than
98% of the 1161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. TARO: 30.63 )
TARO' s 10-Year ROA (%) Range
Min: -17   Max: 30.15
Current: 30.63

-17
30.15
ROC (Joel Greenblatt) (%) 120.57
TARO's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.14 vs. TARO: 120.57 )
TARO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -30.11   Max: 132.39
Current: 120.57

-30.11
132.39
Revenue Growth (3Y)(%) 22.30
TARO's Revenue Growth (3Y)(%) is ranked higher than
90% of the 932 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. TARO: 22.30 )
TARO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.8   Max: 34.7
Current: 22.3

-6.8
34.7
EBITDA Growth (3Y)(%) 63.60
TARO's EBITDA Growth (3Y)(%) is ranked higher than
99% of the 839 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. TARO: 63.60 )
TARO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -24.3   Max: 63.6
Current: 63.6

-24.3
63.6
EPS Growth (3Y)(%) 74.30
TARO's EPS Growth (3Y)(%) is ranked higher than
98% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. TARO: 74.30 )
TARO' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 102.1
Current: 74.3

0
102.1
» TARO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

TARO Guru Trades in Q1 2014

Jim Simons 268,400 sh (+13.98%)
Steven Cohen Sold Out
HOTCHKIS & WILEY 455,252 sh (-14.09%)
» More
Q2 2014

TARO Guru Trades in Q2 2014

Jim Simons 371,200 sh (+38.30%)
HOTCHKIS & WILEY 510,952 sh (+12.23%)
» More
Q3 2014

TARO Guru Trades in Q3 2014

Jim Simons 397,110 sh (+6.98%)
HOTCHKIS & WILEY 275,064 sh (-46.17%)
» More
Q4 2014

TARO Guru Trades in Q4 2014

Jim Simons 403,500 sh (+1.61%)
HOTCHKIS & WILEY 211,499 sh (-23.11%)
» More
» Details

Insider Trades

Latest Guru Trades with TARO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.60
TARO's P/E(ttm) is ranked higher than
94% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 64.60 vs. TARO: 14.60 )
TARO' s 10-Year P/E(ttm) Range
Min: 3.14   Max: 477.06
Current: 14.6

3.14
477.06
Forward P/E 14.93
TARO's Forward P/E is ranked higher than
92% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TARO: 14.93 )
N/A
PE(NRI) 14.60
TARO's PE(NRI) is ranked higher than
95% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.40 vs. TARO: 14.60 )
TARO' s 10-Year PE(NRI) Range
Min: 3.13   Max: 540.67
Current: 14.6

3.13
540.67
P/B 4.70
TARO's P/B is ranked higher than
62% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. TARO: 4.70 )
TARO' s 10-Year P/B Range
Min: 1.07   Max: 6.4
Current: 4.7

1.07
6.4
P/S 8.01
TARO's P/S is ranked lower than
58% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. TARO: 8.01 )
TARO' s 10-Year P/S Range
Min: 0.61   Max: 9.63
Current: 8.01

0.61
9.63
PFCF 24.60
TARO's PFCF is ranked higher than
89% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TARO: 24.60 )
TARO' s 10-Year PFCF Range
Min: 4.51   Max: 28.21
Current: 24.6

4.51
28.21
POCF 22.27
TARO's POCF is ranked higher than
85% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.91 vs. TARO: 22.27 )
TARO' s 10-Year POCF Range
Min: 4.27   Max: 264.5
Current: 22.27

4.27
264.5
EV-to-EBIT 11.43
TARO's EV-to-EBIT is ranked higher than
93% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.18 vs. TARO: 11.43 )
TARO' s 10-Year EV-to-EBIT Range
Min: -2422.9   Max: 59.6
Current: 11.43

-2422.9
59.6
PEG 0.29
TARO's PEG is ranked higher than
99% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TARO: 0.29 )
TARO' s 10-Year PEG Range
Min: 0.29   Max: 1.34
Current: 0.29

0.29
1.34
Shiller P/E 27.00
TARO's Shiller P/E is ranked higher than
90% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TARO: 27.00 )
TARO' s 10-Year Shiller P/E Range
Min: 6.13   Max: 50.12
Current: 27

6.13
50.12
Current Ratio 5.07
TARO's Current Ratio is ranked higher than
88% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. TARO: 5.07 )
TARO' s 10-Year Current Ratio Range
Min: 0.79   Max: 7.27
Current: 5.07

0.79
7.27
Quick Ratio 4.60
TARO's Quick Ratio is ranked higher than
88% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TARO: 4.60 )
TARO' s 10-Year Quick Ratio Range
Min: 0.55   Max: 6.3
Current: 4.6

0.55
6.3
Days Inventory 239.57
TARO's Days Inventory is ranked higher than
59% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. TARO: 239.57 )
TARO' s 10-Year Days Inventory Range
Min: 142.99   Max: 261.48
Current: 239.57

142.99
261.48
Days Sales Outstanding 102.20
TARO's Days Sales Outstanding is ranked higher than
68% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. TARO: 102.20 )
TARO' s 10-Year Days Sales Outstanding Range
Min: 57.09   Max: 160.16
Current: 102.2

57.09
160.16

Valuation & Return

vs
industry
vs
history
Price/Net Cash 13.70
TARO's Price/Net Cash is ranked higher than
89% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TARO: 13.70 )
TARO' s 10-Year Price/Net Cash Range
Min: 6.83   Max: 92.19
Current: 13.7

6.83
92.19
Price/Net Current Asset Value 9.10
TARO's Price/Net Current Asset Value is ranked higher than
88% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TARO: 9.10 )
TARO' s 10-Year Price/Net Current Asset Value Range
Min: 3.31   Max: 730.23
Current: 9.1

3.31
730.23
Price/Tangible Book 4.70
TARO's Price/Tangible Book is ranked higher than
71% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. TARO: 4.70 )
TARO' s 10-Year Price/Tangible Book Range
Min: 0.89   Max: 15.98
Current: 4.7

0.89
15.98
Price/DCF (Projected) 1.70
TARO's Price/DCF (Projected) is ranked higher than
92% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TARO: 1.70 )
TARO' s 10-Year Price/DCF (Projected) Range
Min: 1.44   Max: 729.68
Current: 1.7

1.44
729.68
Price/Median PS Value 3.80
TARO's Price/Median PS Value is ranked lower than
51% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TARO: 3.80 )
TARO' s 10-Year Price/Median PS Value Range
Min: 0.18   Max: 4.33
Current: 3.8

0.18
4.33
Price/Peter Lynch Fair Value 0.60
TARO's Price/Peter Lynch Fair Value is ranked higher than
99% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. TARO: 0.60 )
TARO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.13   Max: 33.94
Current: 0.6

0.13
33.94
Price/Graham Number 1.80
TARO's Price/Graham Number is ranked higher than
87% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.40 vs. TARO: 1.80 )
TARO' s 10-Year Price/Graham Number Range
Min: 0.4   Max: 10.12
Current: 1.8

0.4
10.12
Earnings Yield (Greenblatt) 8.50
TARO's Earnings Yield (Greenblatt) is ranked higher than
92% of the 1148 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. TARO: 8.50 )
TARO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.7   Max: 21.8
Current: 8.5

1.7
21.8
Forward Rate of Return (Yacktman) 52.12
TARO's Forward Rate of Return (Yacktman) is ranked higher than
98% of the 576 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.03 vs. TARO: 52.12 )
TARO' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -22.3   Max: 53.8
Current: 52.12

-22.3
53.8

Analyst Estimate

Mar15
EPS($) 10.40
EPS without NRI($) 10.40

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:TAL.Germany,
Taro Pharmaceutical Industries Ltd was incorporated under the laws of the State of Israel in 1959 under the name Taro-Vit Chemical Industries Ltd. In 1984, it changed its name to Taro Vit Industries Ltd. and in 1994 it changed its name to Taro Pharmaceutical Industries Ltd., which was the name of a subsidiary of Taro Vit Industries Ltd. incorporated under the laws of the State of Israel in 1950. In 1961, the Company completed the initial public offering of its ordinary shares. The Company is a multinational, science-based pharmaceutical company. It develops, manufactures and markets Rx and OTC pharmaceutical products primarily in the United States, Canada and Israel. Its primary areas of focus include semi-solids formulations such as creams and ointments and other dosage forms such as liquids, capsules and tablets, mainly in the dermatological and topical, cardiovascular, neuropsychiatric and anti-inflammatory therapeutic categories. The Company markets more than 200 pharmaceutical products in over 25 countries. The Company competes with the original manufacturers of the brand-name equivalents of its generic products, other generic drug manufacturers including brand-name companies that also manufacture generic drugs or license their products to other generic drug manufacturers and manufacturers of new drugs that may compete with its generic drugs. In Canada, the Company's competition includes Merck Canada Inc., Pfizer Canada Inc., Janssen Inc., Novartis Pharmaceuticals Canada Inc., GlaxoSmithKline Inc., Valeant Canada, AstraZeneca Canada, Johnson & Johnson Inc., Bayer Inc. and Bristol-Myers Squibb Canada. The Company also competes with other manufacturers of generic products, such as Apotex Inc., Teva Canada Limited, Mylan Pharmaceuticals ULC, Sandoz Canada Incorporated and Pharmascience Inc. In Israel, it competes with Teva Pharmaceutical Industries Ltd., Perrigo Israel Pharmaceuticals Ltd., Dexcel Pharma Israel, and Rafa Laboratories Ltd., among others. In addition, many multinational companies, including Bayer AG, Eli Lilly and Company, Merck & Co., Inc. and Pfizer Inc., market their products in Israel.
» More Articles for TARO

Headlines

Articles On GuruFocus.com
Ontario to See $3.66 Billion in Project Construction Starts in Second-Quarter 2015, Fueled by Natura Mar 18 2015 
Pharmaceutical Industry on the Cusp Of Change Jun 02 2014 
Teva Pharmaceutical (TEVA) Dividend Stock Analysis Jun 28 2013 
taro pharma could double Aug 26 2012 
What do people think of TARO Aug 26 2012 
TARO Shares are Mispriced Compared to Competitors Like Perrigo and Teva May 10 2012 
Sun Pharmaceutical Extends Tender Offer for Taro Dec 19 2008 

More From Other Websites
Ontario to See $3.66 Billion in Project Construction Starts in Second-Quarter 2015, Fueled by... Mar 18 2015
Irish Highlanders: Drug Stocks Mallinckrodt, Horizon Pharma Rally Mar 05 2015
A. M. Castle & Co (CAS) and Other Bullish Picks of Raging Capital Mar 04 2015
Taro Provides Results for December 31, 2014 Feb 10 2015
Q3 2015 Taro Pharmaceutical Industries Ltd Earnings Release - After Market Close Feb 10 2015
Taro to Announce Third Quarter Results on February 10, 2015 Feb 05 2015
Taro to Announce Third Quarter Results on February 10, 2015 Feb 05 2015
Spirit Air, Other Leading Stocks Shaping New Bases Jan 29 2015
Taro Announces Results of Its Annual General Meeting of Shareholders Dec 24 2014
Taro Announces Results of Its Annual General Meeting of Shareholders Dec 24 2014
Stock Movers: Why 4 Big Drug Stocks Are Rising Today Nov 18 2014
Taro Provides Results for September 30, 2014 Nov 09 2014
Taro to Announce Second Quarter Results on November 9, 2014 Nov 05 2014
Stock Strength: It's All Relative, And Is Reflected In The RS Line Oct 29 2014
Lessons To Take From Health Care's Strong 2014 And What To Buy Now Aug 25 2014
Large Cap All Time Highs Today... Aug 12 2014
Taro Provides Results for Quarter Ended June 2014 Aug 07 2014
Small-Cap Funds Are In A Lull Aug 07 2014
Taro to Announce Results for Quarter Ended June 30, 2014 Aug 04 2014
TARO PHARMACEUTICAL INDUSTRIES LTD Financials Jul 09 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK